Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan liposome + capecitabine + enlansubemab
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of a liposomal formulation of the topoisomerase I inhibitor irinotecan, the oral fluoropyrimidine prodrug capecitabine, and the PD-1 monoclonal antibody enlansubemab. It is currently being investigated as a neoadjuvant therapy in combination with short-course radiotherapy (SCRT) for patients with locally advanced rectal cancer (LARC). The treatment strategy aims to leverage the cytotoxic effects of chemotherapy and radiation to induce immunogenic cell death, which is further enhanced by the immune checkpoint blockade provided by enlansubemab. This multi-modal approach is designed to improve pathological complete response (pCR) rates and potentially allow for organ preservation through a 'Watch and Wait' (W&W) strategy in responsive patients.
- Other names
- EnlangsumabEnronsubemab
02
Targets
TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on irinotecan liposome + capecitabine + enlansubemab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan liposome + capecitabine + enlansubemab.